DO SERUM ANTI-MULLERIAN HORMON LEVELS ASSOCIATE WİTH ASSISTED REPRODUCTIVE TREATMENT CYCLE OUTCOMES? A RETROSPECTIVE ANALYSİS OF 1544 CYCLES FORM A SINGLE IVF CENTER

Authors : Gülnaz ŞAHİN

Pages : 271-282

View : 9 | Download : 5

Publication Date : 2021-12-30

Article Type : Research Paper

Abstract :Introduction: To evaluate whether there is a predictive value of serum Anti-Mullerian Hormone (AMH) levels on ovarian response and pregnancy outcomes of infertile women undergoing intracytoplasmic sperm injection (ICSI) cycle. Methods: A total of 1544 consecutive ICSI cycles of women aged between 18-45 years, performed in a single tertiary In-Vitro Fertilization (IVF) Center between 2015-2018, were retrospectively analyzed. Along with patients' ages and AMH levels, cycle characteristics, clinical pregnancy and live birth outcomes were evaluated. Age and serum AMH levels were categorized. Regression analyses were used to determine the predictive value of AMH on the ovarian response and clinical pregnancy/live birth outcomes. Results: Among 1544 cycles, 1306 (84.6%) were ended with an embryo transfer cyle. AMH levels were found significantly positively correlated with the numbers of obtained oocytes and 2-pronuclear(2pn) zygotes. AMH value of >1 ng/ml was significantly and independently associated with obtaining more than 5 oocytes (OR: 6.7; 95% CI: 4.9-9.1). The clinical pregnancy and live birth rates per cycle were significantly lower in patients with low AMH for both age =35 years age). Moreover, only age and number of metaphase-2 oocytes were found significant independent predictors for live birth outcome. Conclusion: Although AMH levels are highly correlated with the oocyte yield in ICSI cycles, the ability to predict clinical pregnancy and live births for fresh embryo transfer cycles seems limited. Keywords: AMH, ICSI, clinical pregnancy, live birth
Keywords : AMH, ICSI, clinical pregnancy, live birth, AMH, ICSI, clinical pregnancy, live birth